div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033fdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033fdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033fdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may src=https:reader033fdocumentsusreader033viewer20220421165e93b2d1fe2026340c31a1d9html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 5button div class=trans-image amp-img class=trans-thumb alt=Page 5: Currently the Food and Drug Administration FDA requires the demonstration of bioequivalence of generic drugs to innovator drugs in normal healthy subjects a criterion that may...